AbbVie (ABBV) vs Bristol Myers (BMY): Which is a Better Stock to Buy?
AbbVie Inc. (NYSE:ABBV) closed at $262.82 on October 2, and Bristol Myers Squibb Company (NYSE:BMY) at $61.15. Both spent the last few years doing the same difficult thing.
Abbvie Inc. (ABBV)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 9,497,970 | $2,390,069,445 | +5% | 0.71% |
| 2. | Citadel Investment Group Ken Griffin | 3,169,783 | $797,644,194 | +547% | 0.09% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 2,990,512 | $752,532,440 | +281758% | 0.59% |
| 4. | D E Shaw D. E. Shaw | 2,102,316 | $529,026,798 | +213% | 0.25% |
| 5. | AQR Capital Management Cliff Asness | 2,015,238 | $507,114,594 | +127% | 0.18% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $69.00 | 1,550 | $106,950.00 | 17,644 | 2020-03-20 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-20 | Filing | |
| $67.50 | 800 | $54,000.00 | 16,094 | 2020-03-20 | Filing | |
| $68.18 | 2,200 | $150,004.80 | 15,294 | 2020-03-18 | Filing | |
| $69.00 | 750 | $51,750.00 | 16,844 | 2020-03-30 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $250.00 | 32,710 | $8,177,500.00 | 74,430 | 2026-08-14 | Filing | |
| $233.56 | 5,230 | $1,221,518.80 | 2,654 | 2026-03-04 | Filing | |
| $235.26 | 2,600 | $611,676.00 | 4,619 | 2026-03-02 | Filing | |
| $234.66 | 10,291 | $2,414,886.06 | 7,219 | 2026-03-02 | Filing | |
| $233.51 | 5,777 | $1,348,987.27 | 17,510 | 2026-03-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 46,738 | $12,226,193 | 1.14% | |
| 2. | 29,498 | $7,716,381 | 1.17% | |
| 3. | 26,729 | $6,992,049 | 0.5% | |
| 4. | 7,204 | $1,884,494 | 0.16% | |
| 5. | 6,910 | $1,807,587 | 0.41% |
News See All
Eli Lilly (LLY) and AbbVie (ABBV) Are Expanding Their Pipelines. Their Valuations Tell Two Different Stories
Obesity drugs, pipeline investment, and manufacturing capacity are reshaping the pharmaceutical industry's growth equation.
Can AbbVie’s Backing Help ADARx Win Over Biotech IPO Investors at a $1.74 Billion Valuation?
ADARx Pharmaceuticals is testing investor appetite for another biotech listing, targeting a valuation of as much as $1.74 billion in a U.S. IPO that could raise up to $371.9 million.
10 Best Healthcare Stocks to Buy According to Hedge Funds
Healthcare has rarely been short of investment opportunities, but deciding where to look has become more complicated.
AI Could Give AbbVie (ABBV) a New Route to Long-Term Pipeline Growth
AbbVie Inc. (NYSE:ABBV) and Iambic announced a multi-year collaboration to use Iambic’s AI platform to accelerate small-molecule drug discovery across immunology, neuroscience, and oncology.
Nvidia Backed This AI Drug Startup. AbbVie Just Became a Partner Before Its IPO
AI drug discovery is about to get a public-market test with unusually recognizable backers. Iambic Therapeutics filed for a U.S.
AbbVie (ABBV) Wins EU Approval for Rinvoq in Children. Why a Small Indication Still Matters
AbbVie Inc. (NYSE:ABBV) said on September 22 that the European Commission has approved Rinvoq for children aged two and older with active polyarticular juvenile idiopathic arthritis.
Alzheimer’s-Fighting ADARx Pharmaceuticals Set for Near $2B IPO
ADARx Pharmaceuticals, which is using RNA technology to fight diseases like Alzheimer’s, is targeting a valuation of up to $1.74 billion in its U.S...
AbbVie’s Dividend Growth Remains Solid Despite a Moderate Yield
AbbVie Inc. (NYSE:ABBV) has declared another quarterly dividend of $1.73 per share. The dividend will be paid on November 16, 2026, to shareholders of record as of October 15.
Biogen (BIIB) and AbbVie (ABBV) Get Wolfe Upgrades—Which Pharma Stock Has More Upside?
Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc. (NASDAQ:BIIB) and AbbVie Inc.